Retinoic acid receptor-related receptor alpha (RORalpha) is a prognostic marker for hepatocellular carcinoma
Retinoic acid receptor-related receptor alpha (RORalpha) is a prognostic marker for hepatocellular carcinoma
复制标题
视黄酸受体相关受体α（RORα）是肝细胞癌的预后标志物
DOI：
10.1007/s13277-014-2007-9
复制
发表时间：
2014-08-01
期刊：
影响因子：
--
通讯作者：
Lu, Min-Qiang
中科院分区：
文献类型：
--
作者：
Fu, Rong-Dang;Qiu, Chun-Hui;Lu, Min-Qiang
维甲酸受体相关受体α（ROR α）已被证明在某些类型的实体瘤中发挥肿瘤抑制作用。然而，ROR α的临床特征至今未见报道。本研究探讨了ROR α在肝细胞癌（HCC）中的表达，并评估其与HCC患者临床参数和预后的关系。采用定量逆转录聚合酶链反应（qRT-PCR）和蛋白质印迹法（Western blot）检测20对HCC和相应癌旁组织中ROR α的表达水平。对100例存档的石蜡包埋的HCC样本进行免疫组化。统计学分析评估ROR α表达与临床病理特征之间的相关性。qRT-PCR显示ROR α mRNA在肿瘤组织中的表达较癌旁组织明显下调，Western blot发现ROR α蛋白在肿瘤组织中的表达也明显降低。免疫组化检测显示65%的HCC患者ROR α表达降低.相关分析显示ROR α表达与血清甲胎蛋白（AFP）、病理分级（p<0.001）、肿瘤复发（p= 0.008）和血管浸润（p< 0.001）显著相关。Kaplan-Meier分析显示ROR α低表达患者的总生存期和无病生存期比ROR α高表达患者短（分别为p< 0.001和p = 0.002）。多因素回归分析显示ROR α是总生存期和无病生存期的独立预测因子。总之，我们的研究结果表明，ROR α表达下调与肝癌患者预后不良相关。ROR α可能是肝癌患者新的潜在预后标志物。
Retinoic acid receptor-related receptor alpha (RORalpha) has been proven to play a tumor suppressive role in certain types of solid tumors. However, the clinical characteristic of RORalpha has not been reported by far. This study investigated the expression of RORalpha in hepatocellular carcinoma (HCC) and evaluated its relationship with clinical parameters and prognosis in HCC patients. Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) and Western blot analyses were performed to detect RORalpha expression levels in 20 paired HCC and corresponding adjacent non-cancerous tissues. Immunohistochemistry was performed on 100 archived paraffin-embedded HCC samples. Statistical analyses evaluated the correlations between RORalpha expression and clinicopathological features. qRT-PCR showed that RORalpha mRNA expression was significantly down-regulated in tumors compared to the adjacent non-cancerous tissues, and Western blots found that RORalpha protein expression was also reduced in tumor tissues. Immunohistochemical assays revealed that decreased RORalpha expression was present in 65 % of HCC patients. Correlation analyses showed that RORalpha expression was significantly correlated with serum alpha fetoprotein (AFP,p= 0.005), pathology grade (p< 0.001), tumor recurrence (p= 0.008), and vascular invasion (p< 0.001). Kaplan-Meier analysis revealed that patients with low RORalpha expression levels had a shorter overall and disease-free survival than patients with high expression (p< 0.001 andp= 0.002, respectively). Multivariate regression analysis indicated that RORalpha was an independent predictor for overall survival and disease-free survival. In conclusion, the results of our study showed that down-regulated RORalpha expression was associated with poorer prognosis in HCC patients. RORalpha may be a new potential prognostic marker for HCC patients.